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Ninety-four paltents underwent surgery for aulomrtic im. 
pl~ntrdde c%rdiuvmt%r-de~brlllslor impl%%htitm. Ninety 
patients were dhh%r@ from rhv hap&t with the devlee 
and were snowed up for a mean period Of 17 t 1% mo”*v. 
Forty-six pstirntrorpri~neDd atlear, o dlrhnrgeof the 
device under circom%t%nw ccmsTslrnt with P mlligsnt 
veutricular wrhyihmir. One sudden de&h uwurred. Corn. 
plicatiom includrd prrioper%tivc death (3 pliruts), post- 
oper%ttve ~Bb”tar tiyeardin (12 p~tivnts) and atrial 
Despite the increasing army of available antiarrhythmic 
agents. the criteria used for defining their e0icacy in patients 
with life-threatening ventricuiar arrhythmias are imperfect; 
clinical recurrences of arrhythmia are cummun and monalily 
r%tcs in these patients remain high (t-3). The development if 
the autom%tic implantable cardiove~er-defibrillalor (AICD) 
has been % major advance in the treatment of recurrent 
ventricular tachycardia nd fibrillation. Six and I2 month 
survival rates in patients who have received this device for 
management of refractory ventricular arrhyrhmias ubstan- 
tially exceed those of patients treated with conventional 
media! therapy (4.5). This repon describes 1be safely, 
efficacy and complications associated with Ihe use of the 
tibrtltstion (8 patients), priqwntive mywrdisl inf%rctian 
(1 pslientl and device disehhsrw for sinus taehyeardln %nd 
supr%vent&ulsr z%rrhythmiPs (17 p~tier@. 
Six snd It month uwvi”Sl vats b” nre t&k anatvvli 
““we 98.7 %rid 95.46, revpoetivdy. ihur, ,hv .utemkie 
implantable ardiovrrter&IbrUl%tor is P bl@ly etfwtive 
and relatively low risk trentmeot m&lily forpllknts wilh 
refrsctury liie-thre%te%lng ventrkulsr arrhythmlph 
automatic implantable cardioverter-defibrillator in 94 pa- 
tients with life.threatening ventricular arrhythmias. 
MethOdS 
Study pntieuie. Ninety-four patient% underwent surgery 
at our institutions for automatic implantable cardiovertcr- 
defibrillator implantation between June 1983 and March 
1987. In two of these patients, the defibrillation threshold 
was unacceptnbly high and no pulse generator was im- 
@anted. Another patient, who received a simulator unit ai 
the time of device implautation, died in the periqerative 
period and did not receive a functional pulse generator. 
Including primary implants and pulse generator replace- 
ments, I09 pulse generators were implanted in 91 patients 
during the study period. The 94 paients ranged in age from 
I4 tu 78 years (mean 58.6 -c 11.7); 72 were male and 22 were 
female. The clinic%l cbaiactcristics of these parieuts are 
summarized in Table 1. 
Preap+r%tivrevaluatiun, Before device implantation, car- 
diac catheterization. including wunary arteriogaphy and 
left ventriculography, w%s performed in 93 of the 94 patients. 
One patient. a I5 year old girl, did nut undergo left hart 
mined using m erternal ~=rdiovener-defibrillator capable of 
delivering energy levels between I and 40 1. If a threshold 
~15 J w&c not achieved with the initial lead position. other 
pnrnionr and iedd contieuntions were tested and the wsi- 
non wh the lowest thrkhold was cho%n. A detibrillkon 
threshold of a25 J WPE required for pulse generator imptan- 
iation and a value of 215 J was considered optkd. The 
iampliludc of the electrognm recorded from the sensing 
leads had 10 be ~5 mV during sinus rhythm hefaz place- 
ment of the delke was considered acceptable. Arrhythmia 
ioduclion ~85 repeated after the leads were connected to the 
pulrr generator. and sensing and termination of the arrhytb- 
mm was tha accomplished by the implanted system. 
catheterization; her left veoiricolar ejection fraction was 
determined by radionuclide ventriculography. Electrophy- 
siolwic testing was oerfomted oreooerativelv in all r&rats. 
All p&ads with inducible &ined verric&r &ythmias 
underwent testing during treatment with antiarrhythmic 
drugs (one to seven per patient). All patients also had 24 to 
48 h continuous electmcardiomaohic (EC@ monitoriw be- 
fore surgery. Those who were able to exercise under& 
maximal exercise treadmill testing before implantation or 
just before hospital discharge. 
Dovia impJantatiin. The slmctural and functional char- 
acteristics of the automatic imolantable cardiovener- 
defibrillator syrtem have been prekously described (6-U. 
All patients were monitored intlaoperatively and for 24 to 48 
h postoperatively using indwelling arterial and pulmonary 
arte~l catheters. The surgical approaches employed. and the 
pulse genwator models and delibrillating and sensmg lead 
configurations used, are shown in Table 2. 
FIN innaop~razht- tesriscg of rke device, ventricular fibnl- 
lation and, if possible. sustained ventricular tachycardia 
were induced by ventricular ramp pacing, programmed 
premature stimulation OF the application of alternating cur- 
rent to the epicardium. !Jeftbrillation thresholds were deter- 
Postoperative t sting and f&w-op. &fore hospital dis- 
charge. al! patients except eight who w.d spontaneous 
postope~a~we ventricular lachycardia that was successfully 
lermmated by the automaIic implantable cardioverter- 
defibrillator. underwent testing of their device in the electro- 
physiology laboratory. Ventricular tachycardia or ventricu- 
lar fibrdladon was induced. and proper sencing and 
temunaIion of the arrhvthmia were demonstnted. 
dewce was performed ,o evaloate battery status and to 
determme the number of discharges delivered. In patients 
who experienced device discharges. the activity at the time 
of discharge and any associated symptoms such as palpita- 
tion. rvncope or near ~yncope were recorded. 
N” 0, Padeer 
Statkliml analysis. Unless otherwise specified. data are 
expressed as a mesn ? I standard deviation. Because 
detibrillatiorl thresholds were not nowslly diztlibuted. these 
data are expressed it< median vakles Cnmparisons were 
made by using unpaired I tests or Fisk& exact test when 
appropriate. A variable was deemed significant if the two- 
tailed p value was <O.OS. 
Univanatc analyses of the effects of clinical variables on 
defibrillation rhreshold were performed using theexact Wil- 
coxon test for ordered categorical variables (9) and the 
Mann-Whirnev non~aramctric test for median valuer. Life 
table analysis.was performed by the Kaplan-Meier method. 
Figure 1. Defibrillation thresholds (joules) at the time of initial 
automatic mplamsble cardiovener.deAbriltator implantation i 14 
clients who had received amicdamne lvithin I month before 
&ery as compared with those of LB patients who had not. fhe 
median dehbrtlladon threshold was significantly higher in the amio- 
damne *Lwp ,I5 “erS”E 10 1: p < 0.05, Mann-Whitney tert,. 
Results 
Operative r~tls, Of the 94 primary implantations we 
auemnted. 89 were corn&led with adeouate defibrillation 
thre&ldsa~ Ike rime ofinitial surgery. D&ibrillation thresh- 
olds in these oatients rawed from 5 to Z5 J and were 620 J 
in 88 patient; and 525 .i in the remaining patient. In five 
paticms. all ai whom received amiodarone within I month 
before surgery, a defibrillation threshold of 525 J could not 
be achieved despite testing of multiple detibrillating lead 
positions and configurations including a two patch system. 
intrapericordial patch placement and reversal of defibril- 
lating lead polarity. One of these five patients, whose intra- 
operative threshold was 240 I. died postoperatively. The 
other four patients had repeat hreshold determination after 
6 10 10 weeks without amiodarone therapy. In three of the 
four. the threshold was 5 I5 J at the time of retesting, and a 
pulse generator war implanted. In the fourth patient. tkere 
was no change from the initial threshold of >40 J and he did 
not receive a device. 
from 42 patients, all of whom had a spring-large -patch 
defibrillating lead configuration: their defibrillation threshold 
was determined by repeated isduction of ventricular fibril- 
lation and subsequent defibrillation trials, beginning with 
energy levels of IS to 20 J aud decreasing by 5 J decrements 
Dejbrillarion rhnshoid was compared in padents who 
were and wvre not receiving omiodarone on rhe basis ofdata 
antiamhythmic drug therapy other than amiodaraae had no 
statistically significant effect on defibrillation threshold. 
R waves of t5 mV during sinus rhythm were recorded 
from the sensing electrodes in all patients who had the 
device implanted. As with the defibrillating leads, in several 
eases multiple lead positions were tested before an adequate 
valve was obtained. 
This was accomplished with the aid of pro&mmin~ the 
pacemaker to the lowest possible output. This patient, 
whose initial incision was ubxiphoid, required a left tbora- 
cotom~ for better exposure and testing of multiple sensing 
Thirwenpolienrs hodopermanenrpacemoker at the time 
of ouromaric implanrable cordioverrer-de/ibrillaror implan- 
mlion. len patienls had a bipolar unit; in two patients a 
lead positions. In another patient with a biwlar dual cham- 
unipcdar unit war changed to a bipolar device intraopera- 
tively. and in one patient a enipoler unit was removed and 
not replaced. In one patient with a bipolar ventricular 
pacemaker, several epicardial sensing lead positions were 
tried before one was found that did not result in “double 
counting” of the stimulus artifact and the QRS complex. 
until the lowest et%ctive energy was d&mined. The me- ber &maker (MedtroniE model 7OtX) add a spring-patch 
dian threshold was IO J in 28 patients who either had never defibrillating lead configuration, each defibrillation resulted 
received amiodamne or had not been takine the dme for >I in IS to 20 min aeriwts of mwemaker failure to sense and 
month at rke time of initial defibrillator i~pla.ntati&. This 
compares with I5 1 in I4 patients who had received at least 
2 weeks of amicdarone therapy within I month of implanta- 
tion tp C 0.05, Mann-Whitney test) (p - 0.008, exact 
Wilcoxon test) (Fig. 1). There was no significant di0erence in 
delibrillation thresholds between the I7 patieots who had 
never received amiodarone and the II patients who had 
discontinued the drug at least 1 month before defibrillaior 
implantation; tne median value was IO J in both cases. Age, 
gender. cardiac diagnosis. left ventricular ejection fraction, 
presence or absence of a left ventricular aneurysm and 
capture. The ve&icular spikes were sensed and counted as 
R waves by the cardiover(er-defibrillator. Because of this 
problem. and because the rate of one of the induced tachy 
cardms was less than the cutofl rate of the only available 
device, a simulator unit was implanted. A second epicardial 
patch was also implanted at this time. An evaluation of the 
pacemaker-defibrillator interaction using a patch-patch deli- 
brillating lead configuration was to be performed when 
another pulse generator became available. This patient died 
in the peiiopcmtive period, however, and was not retested. 
TaMe 3. Su:pical Complications in 94 Patientr muthorax and pleural effusion large enough to cause signs of 
No af RliC”li I%) pulmonary conrolidatwn on physical examination, occurred 
Death f 131 
in 21 p&ems W%I. These were more frequent with the left 
P0510Pem!IYe “lnmC”lar tachycardlr ,?~I,, anteriur thoracotamy approach (24 of 63) than with the 
kitwRli”C ama, hbnlladon 8 191 stemotomy C I of 23) and subxiphoid (2 of 8) approaches (p = 
hlln0”~‘” CDrnOliFlliO”~ ?71191 0.W). Althcwh the maioritv of these moblems res&ed 
tlents developed postoperative cardio8enic pulmonary 
edema. which resolved with diuresis. and a third had an 
uncomplicated pertoperative non-Q wave myocsrdial infarc- 
imalanrs were d&live when rerredinrrnoperarive,~. One of lion. Two rnxients devetowd wstooerative tower limb dew 
there was unabl; to synchronize to the R&e and another 
delivered multiple discharges for no apparent reason. 
Sw8ical complications (Table 3). The perioperative mew 
tality rate for patients undergoing initial automatic implant- 
able cardiovener-dofib~llator implantation was 3% (3 of 94). 
One patient died 24 h postoperatively of intrzcmble ventri- 
cular arrhythmias and cardiagenic shock. The second patient 
died of respiratory failure 28 dzye postoperatively after 
having suffered a cerebrovascular accident. 20 episodes of 
sustained ventricular tachycardia nd aspiration pneumonia. 
The third patient died 4 days postoperatively after many 
episodes of sustained ventricular tachycardia, pneumonia 
and rewiratorv failure. Nine other ntients had sustained 
venous &mbosir. Both’ pat&s bad undergone previo& 
femoral vein instrumentation on the involved side during 
electrophyniolo$ testing, but neither had been studied 
within 2 weeks before wgery. 
Some ji~m~~nce in r/w pulse generotor pucker wns 
prescnr pos~opera~ivc~y in the mojoriry of parienrr. This 
resolved spontaneously in most cases but two patients 
required pccket aspiration for large. tense. painful fluid 
accumulatron (n = I) and hemaioma In = Il. Asymptomatic 
paicardial rubs also occurred frequently but only three 
patients developed symptomatic pericarditis with fever, 
pleuritic chesr pain and moderate-sized pericsrdial e&ion 
bv echocardiwrxdw. All three resmmded to a brief course 
ventric&r tafhycardia in the early’ postoperative period: 
- . 
of anti-inflammatory drugs. 
two of there had >ZO episodes in 48 h. As the ECG tracings Tiwre IWW rim cme.s of infecrion involving the pulse 
obtained during the postoperative tachycnrdias were re- genrru~or aad ifs electrodes, one 6 weeks and one 6 months 
corded from a single monitor lead, it was not possible to after implantation. The organism in both cases was Staphy 
determine whether these arrhythmias were the fame as any lococc~rs durew. One of these devices was explanted and the 
of the patients’ preoperative clinical tachycardias. Further- patient rchscd a second implant. The second p:ient. who 
more, several patients had multiple tachycardia rates and imcially refused explantation, was treated with an 8 week 
contigurations. All 12pet’entswithposroperative ntricular course of intravenous antibiotics and did well for 5 months 
tachycardia had received epica:M sensing leads (I? of 65). on oral dicloxacillin until a recurrence of fever and active 
In contrast. none of the 29 patients with endowdial leads infection necessitated enplantation. He is now awaiting a 
had postoperative ventricular t chycardia (p = 0.016). The second implant. 
incidence of postoperative vestricular tachycardia was not Pube generawr rrplacenmt. The only perioperative 
related to the deRbrillatins lead configuration used or to the compliation associated with wise generator eplacement 
preoperative frequency of ventricula; tachycardia. was one case of lower limb d&p WII& thrombosis. 
Postoperative atrio/jibrillotion occurred in ei8hl pat&Is Pmtopratie test&. Postoperatively, the device failed 
(8%) and was more prevalent in patients with the patch- to Wmmale a ventricular arrhythmia in two patients. One 
patch detibrillating lead configuration (19%) than in those patient, whose clinical arrhythmia could not be induced in 
with the spring-patch configuration 13%) (p = 0.013). Five the operating rwm. had a spontaneous episode of ventricu- 
patients received multiple device disrharees on this basis. lx txhycardia postoperatively. Although the rate of the 
includins two in whom a discharge initiated ventricular tachycardia I300 beatslmin) was water than the cutoff rate 
tachycardia that was appropriately sensed and terminated by of the device (174.6 bearslmin)~ the arrhythmia was not 
the device. sensed. This unit, which required both morph&?& and ram 
Postoperative pelmonary complicarions, including left critena for arrhythmia recognition, was exchanged for a 
lower pulmonary lobe collapse. hyporemia (room air, partial “mteunly.. device. which appropriately sensed and termi- 
pressure of oxygen lpOJ <70 mm Hg)). pneumonia. pneu- nated the ventricular tachycardia when tested postopera- 
the tjme of device implantation, had seve& intraopcrative 
fmlures to wrwna~s ventricular fibrillation with the initial 
device discharge and required ri second shock. Although his 
first induced episode of ventricular :rhri!lation intraopera- 
lively was terminated with I5 J. a reproducible defibrillation 
threshold of ~2.5 J could not be obtained. Ventricular 
fibrillation induced in the electroohvsioloav laboratorv oost- 
operativciy was sensed by the deiice b;i not succ&~fully 
converted. Repeat testinp after 7 weeks without mniodaronc 
showed a eonsisteru threshold of 515 I and appropriate 
sensing and termination. of ventricular fibrillation with the 
firs1 delivered discharge. 
Clinical foUow.u~. Ninety patients with uo automatic 
implaniable cnraiov&tcr defibrillator have been followed up 
for a meas of 17 2 IO monthr (range I.5 to 41). Fifty-nine 
patients have e& resoived between i and I10 dscharges 
forsurtainrd venlriculartachycardia, venrricularfihrillation. 
nonsustained ventricular tachycardia, atrial fibrillation with 
a rapid ventricular respawc, sinus tachycardia or normal 
sinus rhythm (as a result of device malfunction) (Table 4). In 
I9 of these patients. at least one discharge was for docu- 
mented sust&cd ventricular tachycardia or ve~wicular Bb- 
rittaion. In 27 others, a history of light-beadednerr, ryncope 
or near ryncope just before device discharge was consistent 
with a ventricular tachyarrhytbmia. Of 63 patients who have 
had their device for >6 months, 51% have experienced a 
discharge thal occurred under ctrcumstanee~ consistent with 
a malignant ventricular arrhythmia. 
A”riorr~,yrhmir drugs were ,rw&d ro conrro/ “Frequenr 
epimder of srmoimd or nonsssrainsd vearricular rachyco,- 
dill 61 44 (4%~ of our prrtimts. Therapy with amiodarone 
was necessary in wdy 15 patients (14%), 4 of whom were 
receiving low doses of the drug for conlrol of atrial fibrilla- 
tion. This is in contrast to the 51 patients (63%) who received 
amiodarone n some time before implantation of the delbril- 
l&or. Twenty-five patients required beta-adrenergir blocker 
therapy for control of maximal sinus heart rate or atrial 
fibrillation. 
Figure 2. Posteroaeterior chest X.ray film showing fracture of 
epicardial sensing lead Wow) in 8 patient who experienced several 
automatic imptaMable eardioverter-de&ritlator discharges during 
doamented normal sinus rhythm. Although unrelaled Lo the lead 
fracture. the inlerclectmde distance of the ratraunling leads ap 
pears to be grater than the manufacturer‘s recommcndsd I to 2 cm. 
period, one each at 4.7,9. 33 and 36 months after implan- 
tation. Three patients died of congestive heart failure and 
one of cardiogenic shock during an ante myneardial infarc- 
iion that was complicated by multiple episodes ofventricular 
fibrillation and successful implantable defibrillator dis- 
charges. There WE one sudden death (1%) in a patient 
whose device failed to terminate ventricular fibrillation de- 
spite four discharges. This patient. who had undergone 
successful cardioversion or defibrillation by his device eight 
times over the preceding 7 months, had been hospitalized for 
severe congestive hean failure 2 w&s before his dea?h. 
Five devices were explanred and not replaced. Two 
patients had cardiac transplantation. two refused reimplan- 
tation after remowl of the original device for infection (one 
patient) or batlery depletion (one patient) and one patient is 
awaiting B second implant after explantation for infection. 
Device failures and lead mmpkations. There were three 
cases of early (<t8 months) battery depletion, two at 13 
months and one at I6 months. 
Three ptxrienfs experienced multiple device dixhurw 
dwing dmrmenled normal sinas rhythm. In one case, 
frncturc of one of the epicardial sensing leads was seen on 
chest X-ray 6!m (Fig. 2). Plxement of au endocardial lead 
restored the normal function of the device. In the other two 
patients chest and abdominal X-ray films revealed normal 
lead positions and no lead fractures were seen. Application 
ofa magnet to lhe devices during arm and nbdomin:l muscle 
exercise shwwd no evidence of myoporential sensmg. Both 
patients were taken to the operafing reem where the pulse 
generator wcket V/BE opened and the dewce and leads were 
further evduated. 
in one of these !wo pa~ientr. ,he pulse generaor delivered 
a misdirected pulse on application of a magnet o the device. 
and ventricular fibrillation was initiated. Because the pulse 
generator war clearly defective, it \~.a removed. In the 
second case. bipolar electrograms recorded from the sensing 
leads. lead impedance an,: pacing lhrcshold all met accepred 
criteria. The pulse geuera,or was. therefore. presumed ,a he 
the cause of the malfunction and was explanled. Bath 
devices were found to be defective by the manufacturer at 
postexplant esting, and neither patient received inappropri- 
ate shocks from the new pulse generalor. 
One orkerpadent experienced n misdirected puke during 
ti magnet tes, and ventricular fibrillation was prectpirated. 
The rhythm was appropriately sensed by the devae, which 
recysled and converted the arrhythmia to nerma, sinus 
rhythm after two shocks. 
Figure 3. Life Iable mlyrir pelfDrmFd by ule Kapir”.Meier melhed 
for 90 p~tirnc~ with the au!ometic implantable cardioverter- 
defibnllamr. There were five deaths during the followvp p&ad. 
only one orwhcch was sudden. Theeand 12 manula”r”i”.l rater we 
98.7 an* YS.Cz. rc.r.ectiYely. The numbers abovethe -$I indicate 
the number of pa,ieetr who remain et risk a, the various fellow-up 
i”,FrY& 
There were fwo cmes ofspring lend migrarion and one of 
endocardial sensing leadmigrofion. In four patients. defects 
in the endocardial sensing lead insulation were found at the 
time of routine pulse generator replxement. Three of these 
were repaired. In one case, the endocardial lead was cspped 
and an epicardial sensing pair was placed on the left ventricle 
through a sebxiphoid incision. 
Wscussion 
ond srsmined vmricrdar rachycordia, wm lrlso commons. 
The incidence of atrial librillalion was greatei in patients 
wth the patch-patch defibrillating lead comiguratian. per- 
haps bxaure of more pericardial irritation with the two 
pat&b. ,han with the spring-patch configuration. Postoper- 
alive ven~riculartaehycanliawas significanlly more cnmmon 
in patients who received epicardial sensing leads than in 
those with endocardial leads. Although one might speculate 
that lhis is due to the trauma caused by the epicxdial 
placement. the imwnance of this observation is unclear- This rtudv constitutes the hirwt series of oatients with 
en eutomati~ implanmble cerdi&rter uefibr&r and the 
longest mean follow-up time described to date. Use of this 
device has resulted in improved survival with acceptable 
operative sod perioperative risk in this patient group, which 
is largely composed of those with significant coronary artery 
disease and severe left vertnicular dysfunction. Fifty-one 
percettt of the patients experienced one or more device 
diezharses that occurred under circumstances cunsislent 
with life-threatening ventricular arrhythmias. Six month and 
I2 month survival rates in this group are 98.7 and 95.4%. 
respeclively (Fig. 3) and exceed those of historical control 
subjects, that is, those patients with life-threatening ventri- 
cular arrhythmias who have been treated with antiarrhyth- 
&xause rev&l of cur p&n& received mul,iple dis- 
charger for pastoprative atrial fibrillarion or ventricular 
tachycardia. or both, our practice now is 10 leave Ihe device 
in the inacIive mode until just before hospiml discharge. 
Leaving the device 06 and performing exlemal cardiover- 
smn. if necessary, spares the pulse generator battery until 
the patient‘s condition can be stabilized. 
Twupnrienrr requiredpe~rs,operarive d ainage ofrhepulse 
penemror pocket. Because aspiration of ,be pulse generator 
packel in patients with a permanent pucemaker has been 
though, 10 lcad to an increased mcidence of infection (1,). 
we recommend that this procedure be reserved for cases in 
which there is a leme, symmeratic effusion that does not 
mic rirug .regimens that have been judged ineffective by respond ,D mere cc&rvarive measaree ouch as pressure 
electrophyoiolo~ic testing or by Helter monitxing and exer- dressings and anti-inflammatory drugs. 
cise stress tesfing. These patients have been reported to Device failmw and !ad conplicstians. When tested post- 
have a 26 ,o 41% rate of sudden i.a,h a, I year (X10). operatwely. the automatic implantable cardioverter- 
Pes~o&w&ive complicalions. The moot commu” postop defibrillator Failed ,o rerminme a sp~ltaneous or induced 
e&w complications were pulmonary complications, which ventricular arrhythmia in only two p&n&. In one p&M. 
occurred most frequeudy in the patiems who had undergone whose clinical techycardia could not be induced inmopera- 
left antr.ior thoracotomy This wgges1s that, when possible. tively. an episode of postoperative ventricular tachycardia 
this approach should be avaided in patients at high risk for was no, sensed by ihe device, which required both role tmd 
postoperative respiraory camplicalionn. morphologic criteria for arrhythmia detection. The tachycar- 
Postoperulive arrhythmks, including arrial fbrillarion dia we exceeded the cutoff rate of the implanted evice by 
I25 bentslmin and failure lo satisfy lbe morphologic criteria any preceding symptoms. in R patient whose maximal benrt 
was the presumed cwse of the detection failure. This rate on an exercise lreadmill test equaled or exceeded the 
emphasizes lbc need lo induce bolh venlric~lar hbrillalwn cutoff rate of the device. Although it is possible that some of 
and the patient’s clinical arrhythmia during inlraopcrative these discbarges were for asymptomatic ventricular arrhyth- 
testing whenever pnnsible. This is especially impatanl when mia?. the biswy and exercise lest results in these patients 
implanting devices that depend on bath rate and morpho- were suggestbe of sinus tachycardia or an increase in the 
logic criteria fir arrhythmia recognition. The only other ventricular response in those patients with atrial fibrillation. 
pstoperative failure lo terminate a ventricular tachywrhytb- To minimize the frequency of this occurrence. all patients 
mia occurred in a patient whose inlraoperativel I induced who are capable of exercising should have exerciSe treadmill 
ven:ricular tibri:lalion was not consistently temdnated by tests either preoperatively or just before hospital discharge. 
the first device dircbame. This exwrience suaests that. If wssible. a bema-adrenerpic btockine went should be used 
provided that Itiefibrillalion thresholds of r%J can be inibose patients whose maximal sir& kle approaches the 
obtained. 21 bm:lh ventricular fibrillation and the clinical culolfrate oftheir device. Patients with alrial fibrillation may 
ventricular tack ycardia can be induced inlraopemtively. and require combination therapy with digoxin. B beta-receptor or 
3) all intraoperUive and pOstoperative wrhytbmins are ter- calcium channel blocker and, occasionally, amiodarone for 
minated bv the first delivered discbarxe. there is no need for adeauale rate control. A device with the binheal c!~lcdf me 
mutine p&implantation testing of these devices. that’will reliably sense the clinical amhythmie should be 
Two pnrimrs received misdirected prdses during rorrrine chosen for each patient. This is p-tiicularly important in 
mogner !erlr and I,ennrrirr,l~r/ihrillorion occurred in both. In younger. mm active patients and in those with a history of 
both. the implantable defibrillalor appropriately sensed the supravenlricular arrhythmias. 
arrhythmia and converted il lo normal sinus rhythm. None- Like others who have reponed their exprienee with the 
theless. all magnet tests should be performed in a monitored automatic impladable cardiovener-defibrillator (5.12). we 
setting where external defibrillation is readily available. have had dificully in determining the appmprialcness d 
Spring Cad migrorinw occurred less commonly in our discharges delivered to asymptomatic patients. erpesially 
patients 13%) compared with the 21% incidence rate remvIed those who were not wrfarminr unusuallv strenuous activi- 
by Ecbl et al. (5) and the 23% rate by Manblinski et al. (12) lies ill the lime of beviee di&~e. decasiinaily. ECG 
in earlier series. The addition ofthe “buttertly” to the spring mnniiaring will nverd frequcnl bunts of ttottrurtained ven- 
teed for anchoring purwes is probably largely responsible lricular taebycardia or a cheat X-ray film or magnet test will 
for these improved results. Both lead migrations in our show evidence of a device or lead matftntcticm. Mare alen. 
patients were discovered on routine chest X-ray film within however. no explanation is found. According to F,eht et al. 
3 months of ~mplardalion and there had been no obvious (5). ambulatory monilorine in their uatients hu rbown that 
device malfunction in either patient. We routinely obtain many epioode.ofventricui~lachyeardiathatare~en~ed 
periodic chest X-ray films in patienls with the spring-patch terminated by the device are asymplomalic. It is possible. 
defibnllating lead conliguralion, especially in the early past. then, that a substantial proportion of unexplained discharges 
operative period. are appropriate responses to ventticular tttchyarrhythmias. 
In onorher rw. (I chest X-ray~?lm wus diagnosric ofon The capability kr arrhythmia recall is not a feature of the 
epirardiol senring ieodfrornwe in a patient who had ape- currently avails5le models but may be incorporated into 
rienccd several device dischzes during documented nor- future veneration devices. 
mal sinus rhythm (Fig. 21. In &me c&s of inappropriate 
shocks occumng during $inus rhythm, noninvasive evahta- 
tion does not reveal the cause of the ma!funclion and Ihe 
pulse generator pocket must be opened lo further assess lead 
ad pulse generator function. Eccause oversewing can 
occur es a result of defects in either the sensing leads or the 
pulse generator. all comtmnents of the implanted system 
should be thomu~bly eva’uated before any are replaced. 
lake pwtltvc dirbarges. Our most frequent complication 
has been Ihal of device discharges for sinus tachycardia or 
supraventricular arrhythmias. usually atrial fibrillation with 
Cdl utliurbylbmk drn# therapy. During the 
iollow-up perial. 4% of our patients received antiarhyth- 
mic drugs to suppress frequent episodes of sustained or 
nonsustained v~:ntricular lachycardia. Only 24% of the pa- 
tients who wcw treated with amiadarone at some lime 
before implantedon received the drug postoperatively. Thus. 
although the awomatic implntttable cardioverterdefibrillator 
may not obviate the need for anliarrhythmic drug therapy. it 
does, in many cases. allow for treatment with less toxic 
agents. 
There are stveral rrossible drun-defibrillator interactions 
a rapid ventricular response; these discharger lbave occurred 
in 17 parienls. In eight of these patients the rhythm WBS 
lbat should be considered wheheh&ing antiarrhylbmic 
therapy for a wtient with an imolanted defibrillator. We 
documented. and m nine others the diagnosis of a false 
positive discharge was inferred from the history of a dis- 
found defib~dt~lion threshold to be significan:ly higher in 
parienls who had received amiodsrone within I month of 
charge delivered during strenuous exenian. in the absence of implantation as compared with xhe threshold in patients who 
plantable ‘eardioverter.defibrii~,e, 
. kwD1 discharp. The vatienr baa
had not. and these :esu!ts se’ee with nrcviou~lv o~M’ihed 
data (13.14). There are, however. w&e conRic%g anmml 
data (IS). Furthermore, res”its from ane canine study (16, 
suggest hat the defibrillation energy requirement may de- 
crease after defibrillator implantation regardless of changes 
in drug therapy. Nonetheless, we recommend that, when- 
ever possible, amiodarone be discontinued before cardio- 
verter implamadan unless there is a high likelihood that the 
patimt till require amiodarone therapy postoperatively. In 
that case. theoatient should be refeiviwthe drueat the time 
of implantation for accurate deChrillati& threshold deter”% 
nation. When amiodarone is added to the therapeutic rcgi- 
men of a patient with a previously implanted device, mduc- 
Sian of vemricular tachycardia or ve”“iculx tibrillado”, or 
both. and testins of the device in the laboratory should be 
considered. especially if the defibrillation threshold is mar- 
Jnal at the lime of implantation or if the rate of the patient‘s 
clinical tachycardia is close to the cutoff rate of the device. 
Furthermore. because several other anliarrhythmic agents 
have been rewrlcd to raise the defibdllation threshold 
(17.18~a”d ma~alsoslow the rate ofventricularlachycardla, 
WC recommend that the automadc implantable cardioverter- 
defibrillatar be implanted while the patient is on the anti- 
aw;e;hmic drag regimen that he is expected to continue at 
Because the currently available models are “cornmilted” 
devices that will deliver a discharge once they have bee” 
triggered by a” arrhythmia, whether or not de arrhythmia 
has self terminated, it should be anticipnted that patients 
with freqnenl runs of “onsustained ventricular tachycardia 
wdl reqnue longam~ antiwrhythmic thempy. Six of our 
patients received multiple device discharges for documented 
nonsustained ventricular tachycardia, including one in 
whom a discharge during normal sinus rhythm induced a 
second, slower ventricular tachycardia that terminaled span. 
taneounly (Fig. 41. 
f&makw.&Rbril&loor inleraclii~“s. Although “I”$, re- 
ported caw “I pacemaker-dePhrillalur interactions have 
involved unipolar pacemaker U”“S (5.8.12.19~. both of the 
prlicnts in our series who had significant pacemaker- 
defibnl:atar inwactions had a bipolar unit. This situalio” 
emphawes the need for meticulous intraoperadve testing 
and programming of all pernxwent pacemakers. The Iowe,t 
outpot and highest sensitivity compatible with proper pace- 
maker function should he chosen. The sensing leads should 
be pos”ioned ar far PS possible from the pacing leads. This 
maneuver may, however, ioaease the likelihood of “double 
counting” in the presence of slow intraventricular conduc- 
tion and care should be taken in assuring proper sensing and 
rate counting by the device before the final lead position is 
chosen. 
Conelurionr. The automatic implantable cardioverter- 
defibrillator IS a highly effective and relatively ow risk 
ireatment modality for patients with refractory life- 
threatening ventricular arrhyihmias. Proper device selec- 
“on. meticulous intraoperatwe testing and careful clinical 
follow-up are essential for opdmal results. 
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